Lawson cyclotron to produce new imaging agent that may better locate prostate cancer
Lawson Health Research Institute is the first in Canada to enter a sublicense agreement with The Centre for Probe Development and Commercialization (CPDC) to produce PSMA-1007, a new imaging agent that could help improve the detection of prostate cancer. The radiopharmaceutical tracer can locate and...